KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Ratio (2016 - 2025)

Historic Equity Ratio for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 0.71.

  • TherapeuticsMD's Equity Ratio rose 359.94% to 0.71 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.71, marking a year-over-year increase of 359.94%. This contributed to the annual value of 0.71 for FY2024, which is 425.58% up from last year.
  • As of Q3 2025, TherapeuticsMD's Equity Ratio stood at 0.71, which was up 359.94% from 0.71 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Equity Ratio ranged from a high of 0.71 in Q3 2025 and a low of 1.05 during Q1 2022
  • Moreover, its 5-year median value for Equity Ratio was 0.56 (2023), whereas its average is 0.26.
  • In the last 5 years, TherapeuticsMD's Equity Ratio plummeted by 256113.22% in 2022 and then surged by 42591.66% in 2023.
  • TherapeuticsMD's Equity Ratio (Quarter) stood at 0.55 in 2021, then soared by 170.33% to 0.39 in 2022, then surged by 74.06% to 0.68 in 2023, then rose by 4.26% to 0.71 in 2024, then grew by 0.66% to 0.71 in 2025.
  • Its Equity Ratio was 0.71 in Q3 2025, compared to 0.71 in Q2 2025 and 0.7 in Q1 2025.